Cargando…
Effective Inhibition of Xenografts of Hepatocellular Carcinoma (HepG2) by Rapamycin and Bevacizumab in an Intrahepatic Model
PURPOSE: Hepatocellular carcinoma (HCC) displays a characteristic hypervascularity and depends on angiogenesis for tumor growth, which thus provides a potential target for therapeutic approaches to HCC. In this study, through the use of combined micro-positron emission tomography (PET)/computed tomo...
Autores principales: | Ong, Lai-Chun, Song, In-Chin, Jin, Yi, Kee, Irene H. C., Siew, Eeyan, Yu, Sidney, Thng, Choon-Hua, Huynh, Hung, Chow, Pierce K. H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719751/ https://www.ncbi.nlm.nih.gov/pubmed/19330383 http://dx.doi.org/10.1007/s11307-009-0213-4 |
Ejemplares similares
-
A Dual Tracer (18)F-FCH/(18)F-FDG PET Imaging of an Orthotopic Brain Tumor Xenograft Model
por: Fu, Yilong, et al.
Publicado: (2016) -
BC047440 antisense eukaryotic expression vectors inhibited HepG(2) cell proliferation and suppressed xenograft tumorigenicity
por: Lu, Zheng, et al.
Publicado: (2012) -
Anticancer Effect of Nemopilema nomurai Jellyfish Venom on HepG2 Cells and a Tumor Xenograft Animal Model
por: Lee, Hyunkyoung, et al.
Publicado: (2017) -
Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway
por: Qiang, Shi Qing, et al.
Publicado: (2021) -
NR6A1 regulates lipid metabolism through mammalian target of rapamycin complex 1 in HepG2 cells
por: Wang, Yinfang, et al.
Publicado: (2019)